Search Results
May 13, 2026, 23:08 ET Piramal Pharma Solutions enthüllt hochmoderne Payload-Linker-Suite in seinem Werk in Riverview, Michigan
Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Herstellungsunternehmen (Contract Development and Manufacturing Organization, CDMO) und Teil der Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) („PPS"), hat in seiner Wirkstoffproduktionsstätte in Riverview, Michigan, offiziell
More news about: Piramal Pharma Solutions
May 13, 2026, 10:45 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
May 13, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPS"), has officially unveiled a new, state-of-the-art payload-linker development
More news about: Piramal Pharma Solutions
May 13, 2026, 10:37 ET Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
May 13, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA) (BSE: 543635) ("PPS"), has officially unveiled a new, state-of-the-art payload-linker development
More news about: Piramal Pharma Solutions
May 13, 2026, 08:00 ET Andelyn Biosciences Receives Dark Horse Consulting Certification of Gene Therapy Manufacturing Systems and Capabilities within its Initiative for Certification of Manufacturing Capabilities (ICMC™) Program
industry-wide gap in independent evaluation of CDMO capabilities to support advanced therapeutics manufacturing. The program's evaluation criteria are based on global regulatory standards for commercial manufacturing. Without such assessment, selecting a CDMO for therapeutic developers can become a risky
More news about: Andelyn Biosciences
May 12, 2026, 12:00 ET Caring Cross Announces Promising Clinical Data with Single-Dose anti-HIV CAR-T Cell Therapy
Lentiviral vectors used to manufacture Caring Cross advanced therapy medicinal products are manufactured by Vector BioMed, a public benefit corporation and CDMO specializing in rapid manufacturing solutions to provide the industry with affordable, high-quality GMP lentiviral vectors. For more information on
More news about: Caring Cross
May 12, 2026, 11:00 ET Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical
More news about: Porton Advanced
May 12, 2026, 10:38 ET Medical Device Contract Manufacturing Market 2026-2031: To Reach USD 171.03 Billion by 2031 As Precision Manufacturing Technologies Gain Traction, Says Mordor Intelligence
Pharmaceutical CDMO 2.0 Market Size: The pharmaceutical CDMO 2.0 market is expected to grow from USD 173.55 billion in 2025 to USD 272.85 billion by 2031 at a CAGR of 7.89%. Market expansion
More news about: Mordor Intelligence Private Limited
May 12, 2026, 09:00 ET Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical
More news about: Porton Advanced
May 12, 2026, 08:30 ET From hPSCs to Epithelial Cell Lines: Accelerating IND-Enabling Cell Line Development with VIPS PRO, Upcoming Webinar Hosted by Xtalks
standardized, audit-ready documentation for tech transfer. The session will highlight CCRM/OmniaBio's successful implementation of this approach in a real-world CDMO setting, demonstrating how early clonal confidence derisks downstream development while enabling scalable, GMP-aligned workflows for primary cells.Register
More news about: Xtalks
May 12, 2026, 08:00 ET Andelyn Biosciences Launches LVV Curator® Platform, Bringing Proven Viral Vector Platform Pedigree to Lentiviral Vector Manufacturing for Cell Therapies
May 12, 2026 /PRNewswire/ -- Andelyn Biosciences, a leading cell and gene therapy contract development and manufacturing organization (CDMO), today announced the launch of its LVV Curator® Platform, a standardized lentiviral vector (LVV) manufacturing solution built on the same proven modular
More news about: Andelyn Biosciences
May 12, 2026, 04:13 ET Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
Porton AdvancedPorton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has dual-headquarters in Cranbury, New Jersey, and Suzhou, China, providing end-to-end CDMO solutions for ATMPs including plasmids, viral vectors, cell therapy and nucleic acid
More news about: Porton Advanced
May 11, 2026, 13:27 ET Avid Bioservices Appoints Kerri McCullough Wood as Chief Commercial Officer
May 11, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kerri McCullough Wood as Chief Commercial Officer.
More news about: Avid Bioservices
May 11, 2026, 08:01 ET Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
lymphocyte exhaustion. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) offering biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to advance
More news about: Valion Bio, Inc.
May 11, 2026, 07:51 ET ProBio and Curocell Achieve Key CAR-T Milestone with BLA Regulatory Approval and Commercial Readiness
Korea but also reinforces the global potential of innovative CAR-T therapies. At ProBio, we remain committed to empowering our partners with integrated CDMO solutions to accelerate the development and commercialization of advanced therapies worldwide.""The approval of Rimqarto is highly meaningful
More news about: ProBio Inc.
May 07, 2026, 09:00 ET GI Partners Completes Acquisition of the CDMO and Cell Solutions Businesses from Charles River Laboratories and forms Rose BioSolutions
Partners, a leading private investment firm, today announced it has completed the acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International, Inc., forming Rose BioSolutions ("Rose Bio"), a leading provider of advanced
More news about: GI Partners
May 06, 2026, 08:30 ET Seamless Biopharmaceutical Development for Accelerated Validation Readiness, Upcoming Webinar Hosted by Xtalks
this free webinar, understand the key differences between early-stage and late-stage biopharmaceutical development. Attendees will learn how integrated CDMO models can accelerate development timelines. The featured speakers will discuss how process understanding, Quality by Design and validation strategies
More news about: Xtalks
May 06, 2026, 08:08 ET Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
and we are positioned to deliver for cancer patients, for the Strategic National Stockpile, and for the broader biologics industry as a third-party CDMO partner."Entolimod is a Toll-like receptor 5 (TLR5) agonist with broad therapeutic potential. The company is advancing Entolimod with the U.S.
More news about: Valion Bio, Inc.
May 06, 2026, 07:00 ET Cytora Ltd. Appoints Dr. Thomas Serena, MD, World‑Renowned Wound Care Expert to Scientific Advisory Board to Lead Patient Treatment Access and Data Collection for CytoraStem™ human Oral Mucosa Stem Cell (hOMSC) Therapy
manufacturing organization (CDMO) specializing in the development and manufacture of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility and entrepreneurial spirit of a specialist CDMO with deep technical
More news about: Cytora
May 05, 2026, 11:48 ET Alcami Completes Acquisition of Tjoapack
Expanding Alcami's CDMO capabilities across the U.S. and Europe, strengthening packaging scale and supply chain redundancy for pharmaceutical and biotech customersWILMINGTON, N.C., May 5, 2026 /PRNewswire/
More news about: Alcami
May 05, 2026, 09:00 ET Made Scientific and RoosterBio Announce Strategic Technology and Supply Partnership to Expand Scalable MSC and Extracellular Vesicle Manufacturing
manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise
More news about: Made Scientific, Inc.
May 05, 2026, 09:00 ET RoosterBio and Made Scientific Announce Strategic Technology and Supply Partnership to Expand Scalable MSC and Extracellular Vesicle Manufacturing
manufacturing organization (CDMO) specializing in the development, manufacturing, and release of autologous and allogeneic cell therapy products for clinical and commercial supply. Headquartered in Princeton, New Jersey, Made Scientific combines the agility of a specialist CDMO with the deep technical expertise
More news about: RoosterBio, Inc.
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
LONDON, May 5, 2026 /PRNewswire/ -- Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen Partners with Elaaj Bio to Advance Gene Therapy Program for CDKL5 Deficiency Disorder
LONDON, May 5, 2026 /PRNewswire/ -- Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (rAAV) gene therapies, announced today a partnership with Elaaj Bio, a biotechnology company focused
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen geht Partnerschaft mit Elaaj Bio ein, um das Gentherapieprogramm für die CDKL5-Defizienz-Erkrankung voranzutreiben
LONDON, 5. Mai 2026 /PRNewswire/ -- Viralgen, ein führendes Auftragsentwicklungs- und Produktionsunternehmen (CDMO), das sich auf Gentherapien mit rekombinanten adeno-assoziierten Viren (rAAV) spezialisiert hat, gab heute eine Partnerschaft mit Elaaj Bio bekannt,
More news about: Viralgen
May 05, 2026, 08:30 ET Viralgen y Elaaj Bio impulsan un programa de terapia génica para el trastorno por deficiencia de CDKL5
LONDRES, 5 de mayo de 2026 /PRNewswire/ -- Viralgen, una organización líder en desarrollo y fabricación por contrato (CDMO) especializada en terapias génicas con virus adenoasociados recombinantes (rAAV), anunció hoy una alianza con Elaaj Bio, una empresa de biotecnología
More news about: Viralgen